3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
25
Lung Neoplasms
12
Carcinoma, Hepatocellular
9
Small Cell Lung Carcinoma
7
Cholangiocarcinoma
5
Biliary Tract Neoplasms
5
Neoplasms
4
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Carcinoma
3
Breast Neoplasms
3
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Bile Duct Neoplasms
2
Unresectable Hepatocellular Carcinoma
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Respiratory Tract Diseases
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Interventions
Cisplatin
14
Magnetic Resonance Spectroscopy
12
Specimen Handling
10
Platinum
9
1,2-diaminocyclohexaneplatinum II citrate
9
Radiotherapy
7
Radiotherapy, Intensity-Modulated
5
Radiation
5
Carboplatin
5
Biopsy
4
Taxes
3
Surveys and Questionnaires
3
Paclitaxel
3
Nivolumab
3
pembrolizumab
2
Radiotherapy, Image-Guided
2
Observation
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Chemoradiotherapy
2
Cetuximab
2
(225)Ac-DOTA-c(RGDyK)
2
merphos
1
ipatasertib
1
durvalumab
1
dehydroftorafur
1
cemiplimab
1
cabozantinib
1
balstilimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Oropharyngeal Neoplasms
×
durvalumab
×
30 days
×
Clear all
NCT04116047
2026-05-07
CompARE
University of Birmingham
Phase 3
Active not recruiting
785 enrolled